<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601714</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol_BLOOMy study</org_study_id>
    <nct_id>NCT04601714</nct_id>
  </id_info>
  <brief_title>Baseline Cohort Malaria Morbidity Study</brief_title>
  <acronym>BLOOMy</acronym>
  <official_title>Baseline Cohort Study to Assess the Malaria Morbidity in Children Living in Future Malaria Vaccine Candidate Trial Sites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe de Recherche Action en Sante</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe de Recherche Action en Sante</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BLOOMy study is a longitudinal prospective cohort study of healthy children to assess the&#xD;
      incidence of clinical malaria over the main transmission season. Participants will undergo&#xD;
      baseline clinical and biological assessments then will receive a curative dose of either&#xD;
      artesunate or dihydroartemisinin-piperaquine to clear any existing parasitemia. Clearance of&#xD;
      parasites will be confirmed 3 weeks later by Polymerase chain reaction (PCR) and only&#xD;
      participants with negative PCR will be definitively enrolled for the longitudinal follow up.&#xD;
      Both active and passive case detection will be used to ensure that capture of a high&#xD;
      proportion of infections in the cohort is achieved.&#xD;
&#xD;
      Blood samples for immunological assessments will be obtained at Day 0 of each positive blood&#xD;
      smear episode before treatment and at Weeks 4 post treatment.&#xD;
&#xD;
      Participants will be followed for a minimum of six months throughout the malaria peak&#xD;
      transmission season.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BLOOMy study has two co-Primary objectives:&#xD;
&#xD;
        -  To assess the incidence of clinical malaria meeting the primary case definition in&#xD;
           children aged 1.5 to 12 years living in the study area over the main transmission season&#xD;
&#xD;
        -  To assess the occurrence of reinfection following the radical cure of existing&#xD;
           parasitemia.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  To assess the incidence of clinical malaria meeting various secondary cases definition&#xD;
           in children aged 1.5 to 12 years living in the study area over the main transmission&#xD;
           season&#xD;
&#xD;
        -  To measure the immune responses (humoral and cell-mediated) to a panel of malaria&#xD;
           vaccine candidate antigens&#xD;
&#xD;
        -  To assess the molecular force of infection&#xD;
&#xD;
        -  To pilot and standardize malaria morbidity assessment in three phase 2 malaria vaccine&#xD;
           testing sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of clinical malaria episodes per child-year at risk meeting the primary case definition</measure>
    <time_frame>6 months</time_frame>
    <description>The primary case definition: Positive P. falciparum parasitemia at a density &gt; 0 detected by microscopy associated with measured fever (Axillary temperature ≥37.5°C/Tympanic ≥38°C or Forehead temperature ≥37.5°C using non-contact infrared thermometer))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to P. falciparum infection detected by positive thick blood smear within 6 months after the enrolment in African children under natural exposure to P. falciparum by treatment group</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of clinical malaria episodes per child-year at risk meeting the following secondary cases definition</measure>
    <time_frame>6 months</time_frame>
    <description>Second Secondary case definition: Measured fever (Axillary temperature ≥37.5°C/Tympanic ≥38°C or Forehead temperature ≥37.5°C using non-contact infrared thermometer) AND parasitemia of &gt;5,000 parasites (p) / μl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new P. falciparum clones acquired over time</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune responses to malaria candidate vaccines in the consortium portfolio</measure>
    <time_frame>6 months</time_frame>
    <description>Panel of malaria vaccine candidate's antigens such as PfSPZ CVAC, ME-TRAP, R21 (Pre erythrocytic stage antigens) and PfRH5, NPC-SE36 (Blood stage antigens) will be used to assess antibody responses at day 0 and 28 of confirmed episodes of clinical malaria.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">464</enrollment>
  <condition>Malaria</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy children aged 1.5 to 12 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy children aged 1.5 to 12 years&#xD;
&#xD;
          -  Residence in the study area or surroundings for the period of the study&#xD;
&#xD;
          -  Written informed consent from parents/legally acceptable representatives and an assent&#xD;
             for children&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Complicated symptomatic malaria (defined according to standard World Health&#xD;
             Organization criteria)&#xD;
&#xD;
          -  Anaemia (Hb&lt;8g/dL),&#xD;
&#xD;
          -  Any (chronic) illness that requires immediate clinical care.&#xD;
&#xD;
          -  Family history of sudden death or of congenital or clinical conditions known to&#xD;
             prolong QTcB or QTcF interval or e.g. family history of symptomatic cardiac&#xD;
             arrhythmias, with clinically relevant bradycardia or severe cardiac disease&#xD;
&#xD;
          -  Any treatment which can induce a lengthening of QT interval&#xD;
&#xD;
          -  Known history of hypersensitivity or allergic reactions to piperaquine or other&#xD;
             aminoquinolones&#xD;
&#xD;
          -  Receipt of any blood transfusion or immunoglobulins within 3 months&#xD;
&#xD;
          -  Known history of hypersensitivity or allergic reactions to artesunate&#xD;
&#xD;
          -  Severe malnutrition (weight-for-height being below -3 standard deviation or less than&#xD;
             70% of median of the World Health Organization (WHO) normalized reference values).&#xD;
&#xD;
          -  Weight below 5 kg&#xD;
&#xD;
          -  Current or previous participation in malaria vaccine trials&#xD;
&#xD;
          -  Current active participation in any trial involving administration of investigational&#xD;
             drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Alfred Tiono, MD, PhD</last_name>
    <phone>+226 70285726</phone>
    <email>a.tiono@gras.bf</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alphonse Ouedraogo, MD, PhD</last_name>
    <phone>+226 70140811</phone>
    <email>a.ouedraogo@gras.bf</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe de Recherche Action en Santé</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sodiomon B. Sirima, MD, BA, PhD</last_name>
      <phone>+22670200444</phone>
      <email>s.sirima@gras.bf</email>
    </contact>
    <contact_backup>
      <last_name>Alfred B. Tiono, MD, PhD</last_name>
      <phone>+22670285726</phone>
      <email>a.tiono@gras.bf</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
  </location_countries>
  <results_reference>
    <citation>Tiono AB, Kangoye DT, Rehman AM, Kargougou DG, Kaboré Y, Diarra A, Ouedraogo E, Nébié I, Ouédraogo A, Okech B, Milligan P, Sirima SB. Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods. PLoS One. 2014 Jan 24;9(1):e86936. doi: 10.1371/journal.pone.0086936. eCollection 2014.</citation>
    <PMID>24475198</PMID>
  </results_reference>
  <results_reference>
    <citation>Guyant P, Corbel V, Guérin PJ, Lautissier A, Nosten F, Boyer S, Coosemans M, Dondorp AM, Sinou V, Yeung S, White N. Past and new challenges for malaria control and elimination: the role of operational research for innovation in designing interventions. Malar J. 2015 Jul 17;14:279. doi: 10.1186/s12936-015-0802-4.</citation>
    <PMID>26185098</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe de Recherche Action en Sante</investigator_affiliation>
    <investigator_full_name>Sodiomon B.Sirima</investigator_full_name>
    <investigator_title>MD, BA, PhD</investigator_title>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>Cohort</keyword>
  <keyword>Children</keyword>
  <keyword>Epidemiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

